Trial · NCT03318783
Results by group84
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 84
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Participants With Adverse Events | GSK2256294 | Venous Thromboembolism | 2 | Participants | |
| Participants With Adverse Events | Placebo | Venous Thromboembolism | 0 | Participants | |
| Participants With Adverse Events | GSK2256294 | Myocardial Infarction | 0 | Participants | |
| Participants With Adverse Events | Placebo | Myocardial Infarction | 0 | Participants | |
| Participants With Adverse Events | GSK2256294 | Seizure | 1 | Participants | |
| Participants With Adverse Events | Placebo | Seizure | 1 | Participants | |
| Participants With Adverse Events | GSK2256294 | Any Documented Infection | 4 | Participants | |
| Participants With Adverse Events | Placebo | Any Documented Infection | 6 | Participants | |
| Participants With Adverse Events | GSK2256294 | Cerebral Salt Wasting | 3 | Participants | |
| Participants With Adverse Events | Placebo | Cerebral Salt Wasting | 2 | Participants | |
| Participants With Adverse Events | GSK2256294 | Leukopenia | 0 | Participants | |
| Participants With Adverse Events | Placebo | Leukopenia | 1 | Participants | |
| Participants With Adverse Events | GSK2256294 | Aneurysm Rebleed | 0 | Participants | |
| Participants With Adverse Events | Placebo | Aneurysm Rebleed | 1 | Participants | |
| Participants With Adverse Events | GSK2256294 | Acute Respiratory Distress Syndrome | 0 | Participants | |
| Participants With Adverse Events | Placebo | Acute Respiratory Distress Syndrome | 1 | Participants | |
| Participants With Adverse Events | GSK2256294 | Death | 0 | Participants | |
| Participants With Adverse Events | Placebo | Death | 1 | Participants | |
| Study Day 7 and Study Day 10 Serum and CSF EET/ Dihyroxyeicosatrienoic (DHET) Ratio, by Mass Spectroscopic Analysis (ng/mL) | GSK2256294 | Study day 7 CSF 14,15-EET/DHET ratio | .17 | Standard Deviation .07 | ration |
| Study Day 7 and Study Day 10 Serum and CSF EET/ Dihyroxyeicosatrienoic (DHET) Ratio, by Mass Spectroscopic Analysis (ng/mL) | Placebo | Study day 7 CSF 14,15-EET/DHET ratio | .19 | Standard Deviation .16 | ration |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03318783/results